Product overview

Name 1-EBIO
Description Epithelial KCa channel activator. Promotes ESC differentiation into cardiomyocytes.
Purity >98%
Write Your Own Review
You're reviewing:1-EBIO
Rate this item:

Biological Data

Biological description Epithelial KCa channel activator (K0.5 = 84 µM for KCa3.1 channels). Hyperpolarises aortic valve endothelial cells to the same extent as acetylcholine. Also promotes embroyonic stem cell (ESC) differentiation into cardiomyocytes. Displays vasodilation and anticonvulsant properties.

Solubility & Handling

Storage instructions Room temperature
Solubility overview Soluble in DMSO (100mM) and in ethanol (100mM)
Important This product is for RESEARCH USE ONLY and is not intended for therapeutic or diagnostic use. Not for human or veterinary use.

Calculators

Molarity

=
x
x
More Info

Dilution

x
=
x
More Info

Chemical Data

Chemical name 1-Ethyl-2-benzimidazolinone
Molecular Weight 162.19
Chemical structure 1-EBIO  [10045-45-1] Chemical Structure
Molecular Formula C9H10N2O
CAS Number 10045-45-1
PubChem identifier 82320
SMILES CCN1C2=CC=CC=C2NC1=O
InChi InChI=1S/C9H10N2O/c1-2-11-8-6-4-3-5-7(8)10-9(11)12/h3-6H,2H2,1H3,(H,10,12)
InChiKey CXUCKELNYMZTRT-UHFFFAOYSA-N
MDL number MFCD00005715

References for 1-EBIO

References are publications that support the biological activity of the product
  • In vivo characterisation of the small-conductance KCa (SK) channel activator 1-ethyl-2-benzimidazolinone (1-EBIO) as a potential anticonvulsant.

    Anderson NJ et al (2006) Eur J Pharmacol 546(1-3) : 48-53.
  • Reduced hyperpolarization in endothelial cells of rabbit aortic valve following chronic nitroglycerine administration.

    Kusama N et al (2005) Br J Pharmacol 146(4) : 487-97.
  • Pharmacological activation of cloned intermediate- and small-conductance Ca(2+)-activated K(+) channels.

    Syme CA et al (2000) Am J Physiol Cell Physiol 278(3) : C570-81.
  • 1-Ethyl-2-benzimidazolinone stimulates endothelial K(Ca) channels and nitric oxide formation in rat mesenteric vessels.

    Adeagbo AS (1999) Eur J Pharmacol 379(2-3) : 151-9.